Approved accessible "pertuzumab, trastuzumab, and hyaluronidase-zzxf injection"

The fixed-dose combination is indicated for the treatment of early breast cancer (EBC):

Use in combination with chemotherapy for

• • the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than two cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer;
  • the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.

and for the treatment of metastatic breast cancer (MBC):

• Use in combination with docetaxel for the treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

How can 1 go about obtaining pertuzumab, trastuzumab, and hyaluronidase-zzxf injection?

PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 2020
To access pertuzumab, trastuzumab, and hyaluronidase-zzxf injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)

References

• Full prescribing information [FDA]: Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [PDF] Genentech, June 29, 2020
• FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional FDA press release, June 29, 2020
• Phesgo EMA product information sheet, cited on Jan 25, 2021